analyst
CA
AMEX · CATX
Perspective Therapeutics, Inc.
Healthcare · Medical - Devices
$2.73
Down-$0.19 (-6.35%)
Updated Sep 16, 2026, 10:50 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 200.3M
- P/E ratio
- -1.68
- Dividend yield
- 0.00%
- 52-week range
- $1.96 – $6.16
- Volume
- 1.47M
- Avg. volume
- 1.55M
Price performance
CATX price history
1M range · 20 trading sessions · Daily adjusted prices
CATX closed at $2.73 after 20 trading sessions, down 14.95% for the selected period.
- Last close
- $2.73
- Period change
- -14.95%
- Period low
- $2.73
- Period high
- $3.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.88 | $2.89 | $2.66 | $2.73 | 1.47M |
| Sep 14, 2026 | $2.81 | $2.96 | $2.79 | $2.92 | 2.02M |
| Sep 11, 2026 | $2.77 | $2.825 | $2.665 | $2.81 | 2.02M |
| Sep 10, 2026 | $2.96 | $3.01 | $2.75 | $2.77 | 1.58M |
| Sep 9, 2026 | $3.07 | $3.1075 | $2.96 | $2.99 | 1.5M |
| Sep 8, 2026 | $3.12 | $3.18 | $3.02 | $3.12 | 1.06M |
| Sep 4, 2026 | $3.07 | $3.18 | $3.025 | $3.13 | 1.37M |
| Sep 3, 2026 | $3.09 | $3.14 | $3.03 | $3.12 | 931.7K |
| Sep 2, 2026 | $3.10 | $3.235 | $3.025 | $3.10 | 864.64K |
| Sep 1, 2026 | $3.16 | $3.165 | $3.07 | $3.10 | 705.84K |
| Aug 31, 2026 | $3.11 | $3.18 | $3.08 | $3.16 | 910.73K |
| Aug 28, 2026 | $3.16 | $3.17 | $3.075 | $3.11 | 913.34K |
| Aug 27, 2026 | $3.15 | $3.24 | $3.10 | $3.18 | 797.53K |
| Aug 26, 2026 | $3.28 | $3.30 | $3.14 | $3.16 | 799.22K |
| Aug 25, 2026 | $3.22 | $3.325 | $3.20 | $3.29 | 773.77K |
| Aug 24, 2026 | $3.32 | $3.37 | $3.13 | $3.19 | 678.66K |
| Aug 21, 2026 | $3.25 | $3.435 | $3.2223 | $3.30 | 1.14M |
| Aug 20, 2026 | $3.46 | $3.56 | $3.18 | $3.21 | 1.18M |
| Aug 19, 2026 | $3.31 | $3.50 | $3.30 | $3.48 | 1.75M |
| Aug 18, 2026 | $3.21 | $3.25 | $3.125 | $3.21 | 757.95K |
Latest CATX news
The latest Smart Investors Daily articles mentioning CATX.
Stock researchCompany · Overview
CATX research
Overview
Company profile and research snapshot.
Company profile
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Wedbush | Outperform | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 11, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Wedbush | Outperform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.